Point72 Asset Management’s AstraZeneca AZN Stock Holding History

Point72 Asset Management’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$243M	Buy	1,233,965 +307,594	+33%	+$59.3M	0.31%	37
2025 Q4	$170M	Buy	926,371 +641,686	+225%	+$113M	0.19%	77
2025 Q3	$43.7M	Sell	284,685 -558,091	-66%	-$84.5M	0.07%	300
2025 Q2	$118M	Buy	842,776 +248,940	+42%	+$34.9M	0.23%	93
2025 Q1	$87.3M	Buy	593,836 +57,021	+11%	+$8.25M	0.2%	116
2024 Q4	$70.3M	Buy	+536,815	New	+$75.2M	0.16%	147
2024 Q3	–	Sell	-249,475	Closed	-$40.3M	–	1976
2024 Q2	$38.9M	Buy	249,475 +155,775	+166%	+$23.4M	0.1%	263
2024 Q1	$12.7M	Sell	93,700 -47,022	-33%	-$6.23M	0.03%	627
2023 Q4	$19M	Buy	+140,722	New	+$18.3M	0.05%	447
2023 Q3	–	Sell	-165	Closed	-$22.5K	–	2468
2023 Q2	$23.5K	Buy	+165	New	+$24.3K	﹤0.01%	1757
2023 Q1	–	Sell	-769,745	Closed	-$104M	–	2230
2022 Q4	$104M	Sell	769,745 -1,636,085	-68%	-$205M	0.35%	58
2022 Q3	$264M	Buy	2,405,830 +1,419,840	+144%	+$180M	1.05%	5
2022 Q2	$130M	Buy	985,990 +319,090	+48%	+$41.9M	0.55%	26
2022 Q1	$88.5M	Sell	666,900 -217,800	-25%	-$26.1M	0.35%	63
2021 Q4	$103M	Sell	884,700 -334,844	-27%	-$39.4M	0.41%	39
2021 Q3	$146M	Buy	1,219,544 +317,532	+35%	+$37M	0.64%	21
2021 Q2	$108M	Sell	902,012 -874,412	-49%	-$95.9M	0.49%	32
2021 Q1	$177M	Sell	1,776,424 -342,725	-16%	-$34.5M	0.83%	15
2020 Q4	$212M	Buy	2,119,149 +1,876,908	+775%	+$199M	1.03%	7
2020 Q3	$26.6M	Sell	242,241 -105,453	-30%	-$11.7M	0.14%	210
2020 Q2	$36.8M	Buy	347,694 +72,669	+26%	+$7.51M	0.24%	111
2020 Q1	$24.6M	Buy	+275,025	New	+$25.9M	0.2%	145
2019 Q3	–	Sell	-741,099	Closed	-$61.2M	–	1136
2019 Q2	$61.2M	Sell	741,099 -437,862	-37%	-$34.3M	0.32%	73
2019 Q1	$95.3M	Buy	1,178,961 +932,682	+379%	+$73.5M	0.43%	47
2018 Q4	$18.7M	Sell	246,279 -132,421	-35%	-$10.3M	0.09%	276
2018 Q3	$30M	Sell	378,700 -1,022,323	-73%	-$77.3M	0.12%	218
2018 Q2	$98.4M	Sell	1,401,023 -51,745	-4%	-$3.72M	0.39%	56
2018 Q1	$102M	Buy	1,452,768 +990,168	+214%	+$68.6M	0.42%	54
2017 Q4	$32.1M	Sell	462,600 -149,870	-24%	-$10.1M	0.14%	199
2017 Q3	$41.5M	Buy	612,470 +310,916	+103%	+$19.6M	0.19%	148
2017 Q2	$20.6M	Buy	+301,554	New	+$19.7M	0.12%	242
2017 Q1	–	Sell	-338,000	Closed	-$19.7M	–	810
2016 Q4	$18.5M	Buy	+338,000	New	+$19.2M	0.13%	199
2015 Q2	–	Sell	-61,800	Closed	-$4.23M	–	718
2015 Q1	$4.23M	Sell	61,800 -525,600	-89%	-$36.5M	0.03%	462
2014 Q4	$41.3M	Sell	587,400 -23,700	-4%	-$1.7M	0.29%	110
2014 Q3	$43.7M	Buy	611,100 +240,300	+65%	+$17.6M	0.33%	78
2014 Q2	$27.6M	Buy	+370,800	New	+$26.8M	0.18%	162

Other funds holding AZN

Investor AB Stockholm, Sweden $15.1B AUM 29.02% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

VAM

Vanguard Asset Management London, Ec4n 8af $117B AUM

Point72 Asset Management's AZN Position: Q1 2026 in Review

Point72 Asset Management increased its AstraZeneca (AZN) stake by 33% in Q1 2026, buying an estimated $59.3M and bringing the position to 1,233,965 shares worth $243M. The position accounts for 0.31% of the portfolio, ranked #37.

Point72 Asset Management first reported a position in AZN in Q2 2014 and has held it in 36 quarters since. The position peaked at $264M in Q3 2022. 1,377 funds tracked by Wall St. Rank hold AZN as of Q1 2026.

Point72 Asset Management held 1,233,965 shares of AstraZeneca worth $243M as of Q1 2026.
Point72 Asset Management bought 307,594 AstraZeneca shares in Q1 2026, an estimated $59.3M.
AstraZeneca made up 0.31% of Point72 Asset Management's portfolio in Q1 2026, its #37 holding.
Point72 Asset Management first reported a position in AstraZeneca in Q2 2014 and has held it in 36 quarters since.
Point72 Asset Management's AstraZeneca position peaked at $264M in Q3 2022.
1,377 funds tracked by Wall St. Rank held AstraZeneca as of Q1 2026.

Based on Point72 Asset Management's 13F filing for Q1 2026, filed 15 May 2026.